Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Muscle-Invasive Bladder Carcinoma × Taxes × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 35 Pancreatic Neoplasms 31 Carcinoma, Non-Small-Cell Lung 31 Triple Negative Breast Neoplasms 21 Squamous Cell Carcinoma of Head and Neck 11 Ovarian Neoplasms 11 Neoplasm Metastasis 11 Fallopian Tube Neoplasms 11 Lung Neoplasms 10 Uterine Cervical Neoplasms 5 Melanoma 5 Esophageal Squamous Cell Carcinoma 5 Breast Neoplasms, Male 5 Stomach Neoplasms 4 Inflammatory Breast Neoplasms 4 Esophageal Neoplasms 4 Cholangiocarcinoma 4 Carcinoma, Transitional Cell 4 Brenner Tumor 4 Adenocarcinoma Of Esophagus 4 Urinary Bladder Neoplasms 3 Pleural Effusion, Malignant 3 Pancreatic Adenocarcinoma 3 Neoplasms 3 Endometrial Neoplasms 3 Adenocarcinoma 3 Uveal Melanoma 2 Thymoma 2 Small Cell Lung Carcinoma 2 Sarcoma 2

Interventions

Nivolumab 3 Cisplatin 2 Albumin-Bound Paclitaxel 2 tislelizumab 1 spartalizumab 1 Taxes 1 Standard of Care 1 Radiotherapy 1 Immunotherapy 1 Gemcitabine 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05203913 2024-10-04

CNN-BC

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Recruiting

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡